<?xml version="1.0" encoding="UTF-8"?>
<p>Data extracted from the electronic medical record included demographics, prior treatment history, hospital and intensive care unit length of stay, conditioning chemotherapy before CTI, antimicrobial prophylaxis, subtype and duration of leukopenia, antimicrobial treatment received, occurrence and grade of CRS and/or neurotoxicity, serum immunoglobulin G (IgG) and cytokine levels, disease response, allogeneic HSCT after CTI, and survival. Neutropenia was defined as an absolute neutrophil count &lt;500/μl and lymphopenia as an absolute lymphocyte count &lt;300/μl. CRS was defined using the MSKCC grading criteria (
 <xref rid="T1" ref-type="table">Table 1</xref>). CRS grade 0–2 was considered mild, whereas grade ≥3 was considered severe, as described elsewhere [
 <xref rid="CIT0005" ref-type="bibr">5</xref>, 
 <xref rid="CIT0007" ref-type="bibr">7</xref>, 
 <xref rid="CIT0020" ref-type="bibr">20</xref>, 
 <xref rid="CIT0021" ref-type="bibr">21</xref>]. Neurotoxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 [
 <xref rid="CIT0022" ref-type="bibr">22</xref>].
</p>
